Droglican

**Droglican** is an oral fixed-dose combination of chondroitin sulfate sodium and glucosamine hydrochloride, developed by Bioiberica and subsequently acquired by Reig Jofre. Each hard capsule contains 200 mg chondroitin sulfate sodium and 250 mg glucosamine hydrochloride. It is authorized in Spain for symptomatic treatment of moderate-to-severe knee osteoarthritis when combined chondroitin sulfate and glucosamine treatment is appropriate. It is classified as an other specific anti-inflammatory and antirheumatic agent and is administered orally as two capsules three times daily, delivering 1,200 mg/day chondroitin sulfate and 1,500 mg/day glucosamine hydrochloride. ([cima.aemps.es](https://cima.aemps.es/cima/dochtml/ft/71394/FT_71394.html))

Brand names

Droglican

Other names

chondroitin sulfate + glucosamine hydrochloridechondroitin sulfate sodium + glucosamine hydrochlorideCS + GHCS/GHGH + CS